Breast cancer

Partial-breast and reduced-dose radiotherapy are noninferior to the whole-breast equivalent for the prevention of local relapse in women with early breast cancer, UK IMPORT LOW trial data show.

Ashkenazi Jewish women with breast cancer may benefit from comprehensive genetic screening for all breast cancer genes, not just founder mutations in BRCA1 or BRCA2, US researchers report.

Long-term follow-up data from the TEAM trial confirm the suitability of exemestane both as a monotherapy and sequentially after tamoxifen for the treatment of postmenopausal women with hormone receptor-positive early breast cancer.

Click through to read more on this US FDA decision

The 70-gene MammaPrint assay can identify women who have an ultralow risk for death from breast cancer in the long term, potentially allowing their physicians to choose less aggressive treatment, say researchers.

Click here for details on these decisions